Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease

Lucilla Parnetti, Lucia Farotti, Paolo Eusebi, Davide Chiasserini, Claudia De Carlo, David Giannandrea, Nicola Salvadori, Viviana Lisetti, Nicola Tambasco, Aroldo Rossi, Nour K. Majbour, Omar El-Agnaf, Paolo Calabresi

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis. Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer's disease (AD) biomarkers-β-amyloid 1-42 (Aβ42), total tau (t-tau), phosphorylated tau (p-tau)-differentiate PD patients from controls, and that reduced levels of Aβ42 represent a predictive factor for development of cognitive deterioration in PD. In this prospective study carried out in 44 PD patients and 25 neurological controls we wanted to verify whether the combination of CSF α-synuclein species-t-α-syn and o-α-syn-and classical AD biomarkers may help in differentiating PD from neurological controls, and if these biomarkers may predict cognitive decline. The median of follow-up duration was 3 years (range: 2-6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used for monitoring cognitive changes along time, being administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic value, significantly contributing to the discrimination of PD from neurological controls. A greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ42/tau ratios (Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR = 12.52). Low CSF Aβ42 level was associated with a higher rate of MMSE and MoCA decline, confirming its role as independent predictive factor for cognitive decline in PD. None of the other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic value. We conclude that combination of CSF o/t-α-syn and Aβ42/tau ratios improve the diagnostic accuracy of PD. PD patients showing low CSF Aβ42 levels at baseline are more prone to develop cognitive decline.

Original languageEnglish
Article numberArticle 53
JournalFrontiers in Aging Neuroscience
Volume6
Issue numberMAR
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

alpha-Synuclein
Amyloid
Parkinson Disease
Cerebrospinal Fluid
Biomarkers
Alzheimer Disease
Synucleins
tau-1 monoclonal antibody
Area Under Curve
Prospective Studies

Keywords

  • Alpha synuclein
  • Cerebrospinal fluid biomarkers
  • Cognitive decline
  • Parkinson's disease
  • Phosphorylated tau
  • Total tau

ASJC Scopus subject areas

  • Ageing
  • Cognitive Neuroscience

Cite this

Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., ... Calabresi, P. (2014). Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease. Frontiers in Aging Neuroscience, 6(MAR), [Article 53]. https://doi.org/10.3389/fnagi.2014.00053

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease. / Parnetti, Lucilla; Farotti, Lucia; Eusebi, Paolo; Chiasserini, Davide; De Carlo, Claudia; Giannandrea, David; Salvadori, Nicola; Lisetti, Viviana; Tambasco, Nicola; Rossi, Aroldo; Majbour, Nour K.; El-Agnaf, Omar; Calabresi, Paolo.

In: Frontiers in Aging Neuroscience, Vol. 6, No. MAR, Article 53, 2014.

Research output: Contribution to journalArticle

Parnetti, L, Farotti, L, Eusebi, P, Chiasserini, D, De Carlo, C, Giannandrea, D, Salvadori, N, Lisetti, V, Tambasco, N, Rossi, A, Majbour, NK, El-Agnaf, O & Calabresi, P 2014, 'Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease', Frontiers in Aging Neuroscience, vol. 6, no. MAR, Article 53. https://doi.org/10.3389/fnagi.2014.00053
Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D et al. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease. Frontiers in Aging Neuroscience. 2014;6(MAR). Article 53. https://doi.org/10.3389/fnagi.2014.00053
Parnetti, Lucilla ; Farotti, Lucia ; Eusebi, Paolo ; Chiasserini, Davide ; De Carlo, Claudia ; Giannandrea, David ; Salvadori, Nicola ; Lisetti, Viviana ; Tambasco, Nicola ; Rossi, Aroldo ; Majbour, Nour K. ; El-Agnaf, Omar ; Calabresi, Paolo. / Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease. In: Frontiers in Aging Neuroscience. 2014 ; Vol. 6, No. MAR.
@article{08f02c54194c439da260e28eb6e4452d,
title = "Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease",
abstract = "There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis. Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer's disease (AD) biomarkers-β-amyloid 1-42 (Aβ42), total tau (t-tau), phosphorylated tau (p-tau)-differentiate PD patients from controls, and that reduced levels of Aβ42 represent a predictive factor for development of cognitive deterioration in PD. In this prospective study carried out in 44 PD patients and 25 neurological controls we wanted to verify whether the combination of CSF α-synuclein species-t-α-syn and o-α-syn-and classical AD biomarkers may help in differentiating PD from neurological controls, and if these biomarkers may predict cognitive decline. The median of follow-up duration was 3 years (range: 2-6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used for monitoring cognitive changes along time, being administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic value, significantly contributing to the discrimination of PD from neurological controls. A greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ42/tau ratios (Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR = 12.52). Low CSF Aβ42 level was associated with a higher rate of MMSE and MoCA decline, confirming its role as independent predictive factor for cognitive decline in PD. None of the other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic value. We conclude that combination of CSF o/t-α-syn and Aβ42/tau ratios improve the diagnostic accuracy of PD. PD patients showing low CSF Aβ42 levels at baseline are more prone to develop cognitive decline.",
keywords = "Alpha synuclein, Cerebrospinal fluid biomarkers, Cognitive decline, Parkinson's disease, Phosphorylated tau, Total tau",
author = "Lucilla Parnetti and Lucia Farotti and Paolo Eusebi and Davide Chiasserini and {De Carlo}, Claudia and David Giannandrea and Nicola Salvadori and Viviana Lisetti and Nicola Tambasco and Aroldo Rossi and Majbour, {Nour K.} and Omar El-Agnaf and Paolo Calabresi",
year = "2014",
doi = "10.3389/fnagi.2014.00053",
language = "English",
volume = "6",
journal = "Frontiers in Aging Neuroscience",
issn = "1663-4365",
publisher = "Frontiers Research Foundation",
number = "MAR",

}

TY - JOUR

T1 - Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease

AU - Parnetti, Lucilla

AU - Farotti, Lucia

AU - Eusebi, Paolo

AU - Chiasserini, Davide

AU - De Carlo, Claudia

AU - Giannandrea, David

AU - Salvadori, Nicola

AU - Lisetti, Viviana

AU - Tambasco, Nicola

AU - Rossi, Aroldo

AU - Majbour, Nour K.

AU - El-Agnaf, Omar

AU - Calabresi, Paolo

PY - 2014

Y1 - 2014

N2 - There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis. Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer's disease (AD) biomarkers-β-amyloid 1-42 (Aβ42), total tau (t-tau), phosphorylated tau (p-tau)-differentiate PD patients from controls, and that reduced levels of Aβ42 represent a predictive factor for development of cognitive deterioration in PD. In this prospective study carried out in 44 PD patients and 25 neurological controls we wanted to verify whether the combination of CSF α-synuclein species-t-α-syn and o-α-syn-and classical AD biomarkers may help in differentiating PD from neurological controls, and if these biomarkers may predict cognitive decline. The median of follow-up duration was 3 years (range: 2-6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used for monitoring cognitive changes along time, being administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic value, significantly contributing to the discrimination of PD from neurological controls. A greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ42/tau ratios (Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR = 12.52). Low CSF Aβ42 level was associated with a higher rate of MMSE and MoCA decline, confirming its role as independent predictive factor for cognitive decline in PD. None of the other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic value. We conclude that combination of CSF o/t-α-syn and Aβ42/tau ratios improve the diagnostic accuracy of PD. PD patients showing low CSF Aβ42 levels at baseline are more prone to develop cognitive decline.

AB - There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis. Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer's disease (AD) biomarkers-β-amyloid 1-42 (Aβ42), total tau (t-tau), phosphorylated tau (p-tau)-differentiate PD patients from controls, and that reduced levels of Aβ42 represent a predictive factor for development of cognitive deterioration in PD. In this prospective study carried out in 44 PD patients and 25 neurological controls we wanted to verify whether the combination of CSF α-synuclein species-t-α-syn and o-α-syn-and classical AD biomarkers may help in differentiating PD from neurological controls, and if these biomarkers may predict cognitive decline. The median of follow-up duration was 3 years (range: 2-6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used for monitoring cognitive changes along time, being administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic value, significantly contributing to the discrimination of PD from neurological controls. A greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ42/tau ratios (Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR = 12.52). Low CSF Aβ42 level was associated with a higher rate of MMSE and MoCA decline, confirming its role as independent predictive factor for cognitive decline in PD. None of the other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic value. We conclude that combination of CSF o/t-α-syn and Aβ42/tau ratios improve the diagnostic accuracy of PD. PD patients showing low CSF Aβ42 levels at baseline are more prone to develop cognitive decline.

KW - Alpha synuclein

KW - Cerebrospinal fluid biomarkers

KW - Cognitive decline

KW - Parkinson's disease

KW - Phosphorylated tau

KW - Total tau

UR - http://www.scopus.com/inward/record.url?scp=84898031335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898031335&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2014.00053

DO - 10.3389/fnagi.2014.00053

M3 - Article

AN - SCOPUS:84898031335

VL - 6

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

IS - MAR

M1 - Article 53

ER -